Saultz and Lochner’s research have long highlighted how relational continuity enhances trust, communication, and shared ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapeutics CEO Paul Romness and EVERSANA VP of ...

The FDA has a new director for the Center for Drug Evaluation and Research (CDER), with biopharma industry executive George ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

A once-daily tablet that can help people suffering from hay fever caused by birch tree pollen, Alk-Abelló's Itulazax, has ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...

At ASCO 2025, Johnson & Johnson contributed more than 70 abstracts, reflecting the depth of their oncology portfolio, and ...

Using microneedle arrays developed at Carnegie Melon, microdosed with a known chemotherapeutic agent delivered directly to ...